21. Subsequent Events

On July 18, 2019, Dr. Rosenwald acquired 396,825 common shares of the Company at $1.26 per share. The shares were acquired as a result of the prepayment by the Company of $500,000 of debt owed to Dr. Rosenwald that was held in the name of Opus Point Healthcare Innovations Fund, LP (“Opus”), an investment fund co-owned by Dr. Rosenwald, in the form of the Company’s common stock (measured at the closing price on July 18, 2019), under that certain Amended & Restated Credit Facility Agreement , dated as of March 12, 2018, by and between the Company and Opus (the “Opus Credit Agreement”).

On August 7, 2019, the Company provided notice to NAM Biotech Fund II, LLC (“NAMBF”) and NAM Special Situations Fund I QP, LLC (“NAMSS”) of extension by one year of the maturity dates under the 2017 Subordinated Note Financing totaling $28.4 million, of which $12.3 million in the aggregate pertains to NAMBF and $16.1 million in the aggregate pertains to NAMSS.

On August 7, 2019, the Company provided notice to NSC Biotech Opportunities Fund, LLC (“NSCBOF”) and NSC Biotech Opportunities QP Fund, LLC (“NSCBOQPF”) of extension by six months of the maturity dates of the 2018 Venture Notes totaling $21.7 million of which $5.1 million in the aggregate pertains to NSCBOF and $16.6 million in the aggregate pertains to NSCBOQPF.

On August 7, 2019, the Company and Opus executed an amendment to the Opus Credit Agreement, extending the maturity date of $5.2 million owing thereunder by one year.